Early Life and Education
Felix Baker was born in March 1969, laying the foundation for his future in the biotechnology investment space. He earned a Bachelor's Degree in Computer Science from Stanford University, and later a Ph.D. in immunology from Stanford. His academic background included two years of medical school, providing him with a deep understanding of the scientific principles underlying the biotechnology industry.
Rise to Success
Baker's career began in 1994 when he began managing healthcare investments for the Tisch family. In 2000, he co-founded Baker Bros. Advisors with his brother Julian Baker. The firm specializes in biotechnology investments, and has grown into a leading player in the industry, managing over $13.8 billion as of September 2025. The firm's success is tied to advances in genetics and a period of dealmaking in the biotech sector. Baker Bros. Advisors has a concentrated portfolio approach, focusing on high-conviction investments in life sciences companies.
Key Business Strategies
Baker Bros. Advisors is known for its fundamental-driven, long-term investment approach focused primarily on publicly traded biotechnology and life sciences companies. The firm concentrates capital in a select group of high-conviction investments, often taking influential roles to support portfolio companies. They conduct detailed scientific and financial due diligence, resulting in significant position concentrations, and are known for their strong returns. BBA's early investment in Seagen in 2003 resulted in a significant windfall gain when Pfizer acquired the company in 2023.
Philanthropy
Details on Felix Baker's specific philanthropy are not readily available. His firm, Baker Bros. Advisors, focuses on biotech investments and is not known for large-scale public charitable initiatives.
